Alto Neuroscience (NYSE:ANRO) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Alto Neuroscience (NYSE:ANRO) from a strong sell rating to a sell rating in a research report report published on Saturday.

ANRO has been the subject of several other reports. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Wedbush raised their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. JonesTrading cut their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Finally, Bank of America assumed coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $27.54 on Friday. The stock’s fifty day simple moving average is $23.17 and its 200 day simple moving average is $21.18. Alto Neuroscience has a one year low of $2.72 and a one year high of $28.85. The firm has a market cap of $966.52 million, a price-to-earnings ratio of -11.38 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, analysts expect that Alto Neuroscience will post -3.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GK Wealth Management LLC bought a new position in shares of Alto Neuroscience in the second quarter worth about $226,000. Perceptive Advisors LLC grew its stake in shares of Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after purchasing an additional 225,500 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Alto Neuroscience by 131.5% in the first quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock valued at $577,000 after purchasing an additional 14,585 shares in the last quarter. Eversept Partners LP acquired a new stake in shares of Alto Neuroscience in the first quarter valued at approximately $2,814,000. Finally, The Manufacturers Life Insurance Company bought a new position in Alto Neuroscience in the 1st quarter worth approximately $534,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.